acetylcarnitine has been researched along with Migraine Disorders in 1 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagen, K | 1 |
| Brenner, E | 1 |
| Linde, M | 1 |
| Gravdahl, GB | 1 |
| Tronvik, EA | 1 |
| Engstrøm, M | 1 |
| Sonnewald, U | 1 |
| Helde, G | 1 |
| Stovner, LJ | 1 |
| Sand, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study[NCT01695317] | Phase 4 | 72 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary measures will be: Days with migraine; days with headache; hours with headache; headache intensity (0-3 scale) on days with headache; doses of analgesics; doses of triptans; days with sick leave; number of responders (≥ 50% decrease in migraine days compared with baseline); incidence of side effects recorded openly. (NCT01695317)
Timeframe: Last 4 weeks
| Intervention | Headache hours per 4 weeks (Mean) |
|---|---|
| Acetyl-L-carnitine | 36.4 |
| Sugar Pills | 37.0 |
The number of days per 4 weeks with moderate or severe headache lasting ≥ 4 hours or if treated with the patient's usual headache medication (usually a triptan) as the primary endpoint. (NCT01695317)
Timeframe: last 4 weeks
| Intervention | Headache days per 4 weeks (Mean) |
|---|---|
| Acetyl-L-carnitine | 5.1 |
| Sugar Pills | 5.2 |
1 trial available for acetylcarnitine and Migraine Disorders
| Article | Year |
|---|---|
Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Middle Aged; Mig | 2015 |